J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More
Executive Summary
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco: Comments from President-elect Donald Trump hovered over the crowd, but companies aimed to stay focused on moving forward regardless of what policy changes are coming.
You may also be interested in...
Just Trust Me: Most Firms Unwilling To Publicly Pledge Pricing Restraint
Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.
AbbVie’s Cancer Expansion Is Paying Off
Label-expansion plans for Imbruvica, along with approvals for Venclexta and Rova-T headline AbbVie's efforts to build a substantial cancer portfolio. The BTK inhibitor was AbbVie's second-best seller in 2016, passing HCV combo Viekira Pak.
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.